PL3523310T3 - Krystaliczne polimorfy agonisty receptora muskarynowego acetylocholiny - Google Patents

Krystaliczne polimorfy agonisty receptora muskarynowego acetylocholiny

Info

Publication number: PL3523310T3
Authority: PL; Poland
Prior art keywords: polymorphas; acetylcholine; crystalline; receptor agonist; muscarine receptor
Prior art date: 2016-10-05

Application number

PL17788131.5T

Other languages

English (en)

Inventor

Abraham Fisher

Nira Bar-Ner

Manfred Windisch

Original Assignee

Nsc Therapeutics Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-10-05

Filing date

2017-10-05

Publication date

2022-08-29

2017-10-05 Application filed by Nsc Therapeutics Gmbh filed Critical Nsc Therapeutics Gmbh

2022-08-29 Publication of PL3523310T3 publication Critical patent/PL3523310T3/pl

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/10—Spiro-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Diabetes (AREA)
Ophthalmology & Optometry (AREA)
Epidemiology (AREA)
Psychiatry (AREA)
Obesity (AREA)
Hematology (AREA)
Immunology (AREA)
Endocrinology (AREA)
Pulmonology (AREA)
Pain & Pain Management (AREA)
Psychology (AREA)
Urology & Nephrology (AREA)
Dermatology (AREA)
Rheumatology (AREA)
Addiction (AREA)
Toxicology (AREA)
Physical Education & Sports Medicine (AREA)
Gynecology & Obstetrics (AREA)
Cardiology (AREA)
Hospice & Palliative Care (AREA)
Anesthesiology (AREA)
Heart & Thoracic Surgery (AREA)

PL17788131.5T 2016-10-05 2017-10-05 Krystaliczne polimorfy agonisty receptora muskarynowego acetylocholiny PL3523310T3 (pl)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP16192494		2016-10-05
PCT/EP2017/075373 WO2018065529A1 (en)	2016-10-05	2017-10-05	Crystalline polymorphs of a muscarinic acetylcholine receptor agonist

Publications (1)

Publication Number	Publication Date
PL3523310T3 true PL3523310T3 (pl)	2022-08-29

Family

ID=57083221

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL17788131.5T PL3523310T3 (pl)	2016-10-05	2017-10-05	Krystaliczne polimorfy agonisty receptora muskarynowego acetylocholiny

Country Status (30)

Country	Link
US (3)	US11008342B2 (pl)
EP (1)	EP3523310B1 (pl)
JP (3)	JP7163280B2 (pl)
KR (1)	KR102710640B1 (pl)
CN (1)	CN109790180A (pl)
AU (1)	AU2017341088B2 (pl)
CA (1)	CA3036134A1 (pl)
CL (1)	CL2019000532A1 (pl)
CO (1)	CO2019003003A2 (pl)
CY (1)	CY1125464T1 (pl)
DK (1)	DK3523310T3 (pl)
EA (1)	EA201990376A1 (pl)
ES (1)	ES2924432T3 (pl)
HR (1)	HRP20220962T1 (pl)
HU (1)	HUE059720T2 (pl)
IL (2)	IL265747B2 (pl)
LT (1)	LT3523310T (pl)
MA (1)	MA46464B1 (pl)
MD (1)	MD3523310T2 (pl)
MX (1)	MX383581B (pl)
PE (2)	PE20191003A1 (pl)
PH (1)	PH12019550048B1 (pl)
PL (1)	PL3523310T3 (pl)
PT (1)	PT3523310T (pl)
RS (1)	RS63438B1 (pl)
SG (1)	SG11201901612TA (pl)
SI (1)	SI3523310T1 (pl)
SM (1)	SMT202200331T1 (pl)
WO (1)	WO2018065529A1 (pl)
ZA (1)	ZA201901695B (pl)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PL3523310T3 (pl) *	2016-10-05	2022-08-29	Nsc Therapeutics Gmbh	Krystaliczne polimorfy agonisty receptora muskarynowego acetylocholiny
WO2019180224A1 (en) *	2018-03-22	2019-09-26	Nsc Therapeutics Gmbh	Compounds and methods for use in the treatment of microglia-mediated disorders
WO2022098700A1 (en) *	2020-11-03	2022-05-12	Cassava Sciences, Inc.	Inhibiting an immune response mediated by one or more of tlr2, rage, ccr5, cxcr4 and cd4

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4855290A (en)	1985-05-10	1989-08-08	State Of Israel, Represented By Prime Minister's Office, Israel Institute For Biological Research	Derivatives of quinuclidine
US5534520A (en)	1990-04-10	1996-07-09	Fisher; Abraham	Spiro compounds containing five-membered rings
US6797558B2 (en)	2001-04-24	2004-09-28	Micron Technology, Inc.	Methods of forming a capacitor with substantially selective deposite of polysilicon on a substantially crystalline capacitor dielectric layer
EP1395257A1 (en) *	2001-06-12	2004-03-10	Elan Pharmaceuticals, Inc.	Macrocycles useful in the treatment of alzheimer's disease
JP4584706B2 (ja)	2002-05-03	2010-11-24	イスラエルインスティチュートフォーバイオロジカルリサーチ	中枢及び末梢神経系障害を治療するための方法及び組成物、並びにそれらに有用な新規の化合物
EP2488177B1 (en) *	2008-10-31	2016-10-12	Pain Therapeutics, Inc.	Filamin a binding anti-inflammatory and analgesic
PL3523310T3 (pl)	2016-10-05	2022-08-29	Nsc Therapeutics Gmbh	Krystaliczne polimorfy agonisty receptora muskarynowego acetylocholiny
WO2019180224A1 (en)	2018-03-22	2019-09-26	Nsc Therapeutics Gmbh	Compounds and methods for use in the treatment of microglia-mediated disorders

2017
- 2017-10-05 PL PL17788131.5T patent/PL3523310T3/pl unknown
- 2017-10-05 PE PE2019000719A patent/PE20191003A1/es unknown
- 2017-10-05 AU AU2017341088A patent/AU2017341088B2/en active Active
- 2017-10-05 US US16/338,930 patent/US11008342B2/en active Active
- 2017-10-05 HU HUE17788131A patent/HUE059720T2/hu unknown
- 2017-10-05 ES ES17788131T patent/ES2924432T3/es active Active
- 2017-10-05 MA MA46464A patent/MA46464B1/fr unknown
- 2017-10-05 PT PT177881315T patent/PT3523310T/pt unknown
- 2017-10-05 SI SI201731206T patent/SI3523310T1/sl unknown
- 2017-10-05 HR HRP20220962TT patent/HRP20220962T1/hr unknown
- 2017-10-05 CN CN201780060800.4A patent/CN109790180A/zh active Pending
- 2017-10-05 JP JP2019512714A patent/JP7163280B2/ja active Active
- 2017-10-05 PE PE2024002026A patent/PE20250745A1/es unknown
- 2017-10-05 DK DK17788131.5T patent/DK3523310T3/da active
- 2017-10-05 CA CA3036134A patent/CA3036134A1/en active Pending
- 2017-10-05 MD MDE20190908T patent/MD3523310T2/ro unknown
- 2017-10-05 SG SG11201901612TA patent/SG11201901612TA/en unknown
- 2017-10-05 KR KR1020197010921A patent/KR102710640B1/ko active Active
- 2017-10-05 LT LTEPPCT/EP2017/075373T patent/LT3523310T/lt unknown
- 2017-10-05 MX MX2019003748A patent/MX383581B/es unknown
- 2017-10-05 EP EP17788131.5A patent/EP3523310B1/en active Active
- 2017-10-05 PH PH1/2019/550048A patent/PH12019550048B1/en unknown
- 2017-10-05 RS RS20220724A patent/RS63438B1/sr unknown
- 2017-10-05 WO PCT/EP2017/075373 patent/WO2018065529A1/en not_active Ceased
- 2017-10-05 SM SM20220331T patent/SMT202200331T1/it unknown
- 2017-10-05 IL IL265747A patent/IL265747B2/en unknown
- 2017-10-05 EA EA201990376A patent/EA201990376A1/ru unknown
2019
- 2019-02-28 CL CL2019000532A patent/CL2019000532A1/es unknown
- 2019-03-19 ZA ZA2019/01695A patent/ZA201901695B/en unknown
- 2019-03-28 CO CONC2019/0003003A patent/CO2019003003A2/es unknown
2020
- 2020-12-22 US US17/130,564 patent/US11866449B2/en active Active
2022
- 2022-05-18 JP JP2022081233A patent/JP2022119840A/ja active Pending
- 2022-08-04 CY CY20221100533T patent/CY1125464T1/el unknown
2023
- 2023-06-28 IL IL304126A patent/IL304126A/en unknown
- 2023-11-21 US US18/516,585 patent/US20240083914A1/en active Pending
2024
- 2024-01-24 JP JP2024008595A patent/JP2024056724A/ja active Pending

Also Published As

Publication number	Publication date
US20240083914A1 (en)	2024-03-14
HUE059720T2 (hu)	2022-12-28
PH12019550048B1 (en)	2023-12-06
JP2024056724A (ja)	2024-04-23
IL265747B1 (en)	2023-08-01
MA46464B1 (fr)	2022-10-31
CN109790180A (zh)	2019-05-21
DK3523310T3 (da)	2022-08-08
ZA201901695B (en)	2021-08-25
KR20190056398A (ko)	2019-05-24
ES2924432T3 (es)	2022-10-06
US11866449B2 (en)	2024-01-09
EA201990376A1 (ru)	2019-11-29
CL2019000532A1 (es)	2019-07-12
IL304126A (en)	2023-09-01
WO2018065529A1 (en)	2018-04-12
US20200040007A1 (en)	2020-02-06
CY1125464T1 (el)	2025-05-09
IL265747A (en)	2019-06-30
BR112019005450A2 (pt)	2019-06-18
AU2017341088A1 (en)	2019-04-04
KR102710640B1 (ko)	2024-09-27
MX2019003748A (es)	2019-08-12
US20210238195A1 (en)	2021-08-05
JP2019529389A (ja)	2019-10-17
PH12019550048A1 (en)	2019-07-24
MA46464A (fr)	2021-05-26
NZ751538A (en)	2024-10-25
SMT202200331T1 (it)	2022-09-14
MX383581B (es)	2025-03-14
MD3523310T2 (ro)	2022-10-31
JP2022119840A (ja)	2022-08-17
SG11201901612TA (en)	2019-03-28
US11008342B2 (en)	2021-05-18
IL265747B2 (en)	2023-12-01
PE20250745A1 (es)	2025-03-13
CO2019003003A2 (es)	2019-04-12
EP3523310A1 (en)	2019-08-14
EP3523310B1 (en)	2022-05-18
AU2017341088B2 (en)	2021-06-24
SI3523310T1 (sl)	2022-10-28
RS63438B1 (sr)	2022-08-31
LT3523310T (lt)	2022-08-25
CA3036134A1 (en)	2018-04-12
HRP20220962T1 (hr)	2022-10-28
JP7163280B2 (ja)	2022-10-31
PT3523310T (pt)	2022-08-04
PE20191003A1 (es)	2019-07-15

Publication	Publication Date	Title
IL268824A (en)	2019-10-31	Improved antigen binding receptor formats
HRP20181499T1 (hr)	2018-11-30	Bičiklički aza spojevi kao agonisti muskarinskih m1 receptora
PL3660004T3 (pl)	2023-10-02	Związki i sposoby do ukierunkowanej degradacji receptora androgenowego
DK3368060T3 (da)	2020-08-24	Glugacon-receptor-agonister
DK3300500T3 (da)	2020-05-18	Triazolagonister af apj-receptoren
LT3978483T (lt)	2025-02-10	Kristalinis (s)-afoksolanerio tolueno solvatas
EP3521427A4 (en)	2020-04-22	CO-RECEPTOR OF A FRAGRANCE RECEPTOR
IL261461B (en)	2022-01-01	Methods of treating depression using orexin-2 receptor antagonists
IL259947B (en)	2020-10-29	Heteroarylhydroxypyrimidinones as agonists of the apj receptor
EP3732163A4 (en)	2021-07-14	MUSCARIN M4 ACETYLCHOLIN RECEPTOR ANTAGONISTS
DK3297631T3 (da)	2019-11-11	NK-1/NK-3-receptorantagonist til behandling af hedeture
DK3212637T3 (da)	2021-07-12	Dopamin-d3-receptorantagonistforbindelser
EP3286210C0 (en)	2023-10-18	T CELL RECEPTOR
DK3104847T3 (da)	2021-02-01	Hidtil ukendt anvendelse af sigma-1-receptoragonistforbindelser
EP3523315A4 (en)	2020-04-15	INHIBITORS OF THE GLUCOCORTICOID RECEPTOR
DK3713928T3 (da)	2022-04-04	Hidtil ukendte bradykinin-b2-receptorantagonister
EP3846806A4 (en)	2022-06-08	Muscarinic acetylcholine m1 receptor antagonists
EP3665175A4 (en)	2020-12-09	MUSCARIN M4 ACETYLCHOLIN RECEPTOR ANTAGONISTS
EP3394078A4 (en)	2019-11-27	INHIBITORS OF THE GLUCOCORTICIDE RECEPTOR
EP3529267C0 (en)	2023-07-26	T CELL RECEPTOR
EP3697781C0 (en)	2023-06-07	MUSCARINIC ACETYLCHOLINE M4 RECEPTOR ANTAGONISTS
DK3334721T3 (da)	2021-06-28	Cgrp-receptorantagonister
EP3440051A4 (en)	2019-11-27	AGROISTS OF NEUROPEPTIDE RECEPTOR (NPSR)
DK3288294T3 (da)	2019-10-07	In-situ kompensation af akustiske målinger
EP3394079A4 (en)	2019-08-21	INHIBITORS OF GLUCOCORTICOIDREZEPTORS